---
configuration: 
  locale: en-US
  dynamo: mock

--- 
- test: NavigateResetIntent 
- NavigateResetIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
  - response.card.title: "Welcome to Melvin test"
  - response.outputSpeech.ssml: "Welcome to Melvin test version."

---
- test: NavigateGoBackIntent 1
- NavigateGoBackIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
      MELVIN.HISTORY: 
      - melvin_state: 
          gene_name: "TP53"
          data_source: "TCGA"
          study_abbreviation: "BRCA"
          data_type: "MUTATIONS"
        intent: "NavigateMutationsIntent"
        event_type: "analysis_event"
  - response.outputSpeech.ssml: "You have reached the end of analysis series. Please provide a new query."

---
- test: NavigateGoBackIntent 2
- NavigateGoBackIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
      MELVIN.HISTORY:
      - melvin_state:
          gene_name: TP53
          data_source: TCGA
          study_abbreviation: BRCA
          data_type: MUTATIONS
        intent: NavigateMutationsIntent
        event_type: analysis_event
      - melvin_state:
          gene_name: TP53
          data_source: TCGA
          study_abbreviation: BRCA
          data_type: MUTATIONS
        intent: NavigateGoBackIntent
        event_type: navigation_revert_event
      - melvin_state:
          gene_name: TP53
          data_source: TCGA
          study_abbreviation: LIHC
          data_type: MUTATIONS
        intent: NavigateMutationsIntent
        event_type: analysis_event
      - melvin_state:
          gene_name: TP53
          data_source: TCGA
          study_abbreviation: OV
          data_type: MUTATIONS
        intent: NavigateMutationsIntent
        event_type: analysis_event
  - response.outputSpeech.ssml: "TP53 mutations are found in 26 percent of Liver hepatocellular carcinoma patients with 19 amino acid residues recurrently mutated."

---
- test: NavigateRestoreSessionIntent
- NavigateRestoreSessionIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
  - response.outputSpeech.ssml: "Ok. Your last session was restored."
  - response.reprompt.outputSpeech.ssml: "You may continue from your last analysis now."

---
- test: NavigateRepeatIntent
- NavigateRepeatIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
      MELVIN.HISTORY: 
      - melvin_state: 
          gene_name: "TP53"
          data_source: "TCGA"
          study_abbreviation: "BRCA"
          data_type: "MUTATIONS"
        intent: "NavigateMutationsIntent"
        event_type: "analysis_event"
  - response.outputSpeech.ssml: "<speak>Ok, TP53. <prosody rate='110%'>What would you like to know?</prosody></speak>"

---
- test: NavigateCompareIntent_cna_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 has the greatest number of copy number alterations in Sarcoma at 37.6 percent while Braca one has the greatest number of copy number alterations in Uterine Carcinosarcoma at 21.1 percent"

---
- test: NavigateCompareIntent_cna_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Breast invasive carcinoma patients have less copy number alterations in TP53 at 5.7 percent while 11.9 percent of cases have alterations in Braca one."

---
- test: NavigateCompareIntent_cna_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Breast invasive carcinoma patients, CCND1 has the greatest number of copy number alterations at 28.6 percent while HCN2 has the greatest number of copy number alterations in Ovarian serous cystadenocarcinoma at 59.5 percent."

---
- test: NavigateCompareIntent_cna_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has more copy number alterations in Ovarian serous cystadenocarcinoma at 12.5 percent while 11.9 percent of Breast invasive carcinoma cases have alterations."

---
- test: NavigateCompareIntent_gain_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 is the most amplified gene in Ovarian serous cystadenocarcinoma at 9.4 percent while Braca one is the most amplified gene in Esophageal carcinoma at 10.8 percent"

---
- test: NavigateCompareIntent_gain_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Breast invasive carcinoma patients, CCND1 has the greatest number of amplifications at 27.4 percent while MECOM has the greatest number of amplifications in Ovarian serous cystadenocarcinoma at 55.9 percent."

---
- test: NavigateCompareIntent_gain_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Breast invasive carcinoma patients have less amplifications of TP53 at 1.5 percent compared to 3.7 percent at Braca one."

---
- test: NavigateCompareIntent_gain_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has more amplifications in Ovarian serous cystadenocarcinoma at 4.5 percent compared to 3.7 percent of Breast invasive carcinoma cases."

---
- test: NavigateCompareIntent_loss_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 has the greatest number of deletions in Sarcoma at 34.1 percent while Braca one has the greatest number of deletions in Uterine Carcinosarcoma at 15.8 percent"

---
- test: NavigateCompareIntent_loss_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Breast invasive carcinoma patients, KAZN has the greatest number of deletions at 16.9 percent while TCF3 has the greatest number of deletions in Ovarian serous cystadenocarcinoma at 57.7 percent."

---
- test: NavigateCompareIntent_loss_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Breast invasive carcinoma patients have less deletions of TP53 at 4.3 percent compared to 8.2 percent at Braca one."

---
- test: NavigateCompareIntent_loss_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has less deletions in Ovarian serous cystadenocarcinoma at 8 percent compared to 8.2 percent of Breast invasive carcinoma cases."

---
- test: NavigateCompareIntent_mut_cna_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has mutations in 19.4 percent and has copy number of alterations in 5.7 percent of all cases."

---
- test: NavigateCompareIntent_mut_cna_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 is the top mutated gene at 34.3 percent while POLRMT has the greatest number of copy number alterations at 59.5 percent."

---
- test: NavigateCompareIntent_mut_cna_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has mutations in 3 percent of Breast invasive carcinoma patients while 13 percent have copy number alterations. 1 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_ind_cna_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has indels in 4.4 percent and has copy number of alterations in 5.7 percent of all cases."

---
- test: NavigateCompareIntent_ind_cna_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of indels at 8.5 percent while POLRMT has the greatest number of copy number alterations at 59.5 percent."

---
- test: NavigateCompareIntent_ind_cna_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has indels in 1 percent of Breast invasive carcinoma patients while 12 percent have copy number alterations. 0 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_snv_cna_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has SNVs in 23.6 percent and has copy number of alterations in 5.7 percent of all cases."

---
- test: NavigateCompareIntent_snv_cna_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of SNVs at 42.8 percent while DAZAP1 has the greatest number of copy number alterations at 59.5 percent."

---
- test: NavigateCompareIntent_snv_cna_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "CNA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has SNVs in 3 percent of Breast invasive carcinoma patients while 13 percent have copy number alterations. 1 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_mut_gain_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has mutations in 27.7 percent and has gains in 1.3 percent of all cases."

---
- test: NavigateCompareIntent_mut_gain_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 is the top mutated gene at 51 percent while MECOM has the greatest number of gains at 57.4 percent."

---
- test: NavigateCompareIntent_mut_gain_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has mutations in 3 percent of Breast invasive carcinoma patients while 5 percent have gains. 1 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_mut_loss_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has mutations in 27.7 percent and has losses in 4.4 percent of all cases."

---
- test: NavigateCompareIntent_mut_loss_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 is the top mutated gene at 51 percent while PWWP3A has the greatest number of losses at 59.5 percent."

---
- test: NavigateCompareIntent_mut_loss_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has mutations in 2 percent of Breast invasive carcinoma patients while 9 percent have losses. 0 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_ind_gain_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has indels in 4.4 percent and has gains in 1.3 percent of all cases."

---
- test: NavigateCompareIntent_ind_gain_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of indels at 8.5 percent while MECOM has the greatest number of gains at 57.4 percent."

---
- test: NavigateCompareIntent_ind_gain_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has indels in 1 percent of Breast invasive carcinoma patients while 4 percent have gains. 0 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_ind_loss_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has indels in 4.4 percent and has losses in 4.4 percent of all cases."

---
- test: NavigateCompareIntent_ind_loss_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of indels at 8.5 percent while PWWP3A has the greatest number of losses at 59.5 percent."

---
- test: NavigateCompareIntent_ind_loss_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has indels in 1 percent of Breast invasive carcinoma patients while 9 percent have losses. 0 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_snv_gain_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has SNVs in 23.6 percent and has gains in 1.3 percent of all cases."

---
- test: NavigateCompareIntent_snv_gain_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of SNVs at 42.8 percent while MECOM has the greatest number of gains at 57.4 percent."

---
- test: NavigateCompareIntent_snv_gain_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GAIN"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has SNVs in 3 percent of Breast invasive carcinoma patients while 5 percent have gains. 1 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_snv_loss_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has SNVs in 23.6 percent and has losses in 4.4 percent of all cases."

---
- test: NavigateCompareIntent_snv_loss_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of SNVs at 42.8 percent while DAZAP1 has the greatest number of losses at 59.5 percent."

---
- test: NavigateCompareIntent_snv_loss_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has SNVs in percent of Breast invasive carcinoma patients while 9 percent have losses. 0 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_gain_loss_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "amplifications"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has gains in 1.3 percent and has losses in 4.4 percent of all cases."

---
- test: NavigateCompareIntent_gain_loss_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "amplifications"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, MECOM has the highest number of gains at 57.4 percent while PWWP3A has the greatest number of losses at 59.5 percent."

---
- test: NavigateCompareIntent_gain_loss_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "LOSS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "amplifications"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has gains in 4 percent of Breast invasive carcinoma patients while 9 percent have losses. 0 percent of Breast invasive carcinoma patients harbor both alterations."

---
- test: NavigateCompareIntent_snv_ind_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Across all of TCGA, TP53 has SNVs in 23.6 percent and has indels in 4.4 percent of all cases."

---
- test: NavigateCompareIntent_snv_ind_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "OV"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Ovarian serous cystadenocarcinoma patients, TP53 has the greatest number of SNVs at 42.5 percent while TP53 has the greatest number of indels at 8.2 percent."

---
- test: NavigateCompareIntent_snv_ind_GS
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one has SNVs in 2 percent of Breast invasive carcinoma patients while 1 percent have indels. 0 percent of Breast invasive carcinoma patients harbor both alterations."

--- 
- test: NavigateJoinFilterIntent_BRCA
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "breast cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Ok, Breast invasive carcinoma."

--- 
- test: NavigateJoinFilterIntent_MUT
- NavigateJoinFilterIntent:
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Ok, mutations. <prosody rate='110%'>What would you like to know?</prosody>"

--- 
- test: NavigateJoinFilterIntent_Mutations_TP53_BRCA
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
        study_abbreviation: "BRCA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "mutations"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 mutations are found in 30 percent of Breast invasive carcinoma patients with 53 amino acid residues recurrently mutated."

--- 
- test: NavigateJoinFilterIntent_TP53
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Ok, TP53. <prosody rate='110%'>What would you like to know?</prosody>"

--- 
- test: NavigateJoinFilterIntent_Domains_TP53_MUT
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
        data_type: "MUTATIONS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "domains"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "P53 DNA-binding domain and P53 tetramerisation motif are the most affected domains containing 85.8 percent and 5.5 percent of mutations respectively."

--- 
- test: NavigateJoinFilterIntent_Domains_TP53_IND
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "domains"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "P53 DNA-binding domain and P53 tetramerisation motif are the most affected domains containing 65.8 percent and 8.1 percent of indels respectively."

--- 
- test: NavigateJoinFilterIntent_TP53_IND
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "indels"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 indels are found in 26 cancer types. It has most indels in Esophageal carcinoma at 12.1 percent followed by Ovarian serous cystadenocarcinoma at 11.7 percent."

--- 
- test: NavigateJoinFilterIntent_TP53_SNV
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "SNVs"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 SNVs are found in 31 cancer types. It has most SNVs in Uterine Carcinosarcoma at 61.4 percent followed by Ovarian serous cystadenocarcinoma at 58.7 percent."


--- 
- test: NavigateJoinFilterIntent_Domains_TP53_SNV
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
        data_type: "SNV"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "domains"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "P53 DNA-binding domain and P53 tetramerisation motif are the most affected domains containing 89.1 percent and 5.1 percent of SNVs respectively."

--- 
- test: NavigateJoinFilterIntent_TP53_BRCA_OV
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        study_abbreviation: "BRCA"
        data_type: "MUTATIONS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "TP53 mutations are found in 70 percent of Ovarian serous cystadenocarcinoma patients with 65 amino acid residues recurrently mutated."

--- 
- test: NavigateJoinFilterIntent_SV-MD_TP53_BRCA
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
        data_source: "TCGA"
        gene_name: "TP53"
        data_type: "STRUCTURAL_VARIANTS"
        study_abbreviation: "BRCA"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "most affected domains"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "P53 DNA-binding domain and P53 tetramerisation motif are the most affected domains containing 88 percent and 5.3 percent of mutations respectively."

---
- test: NavigateCompareIntent_cna_Error
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "The data type is missing for comparison."

--- 
- test: NavigateJoinFilterIntent_Error
- NavigateJoinFilterIntent:
  - request.session.attributes:
      MELVIN.STATE:
  - response.outputSpeech.ssml: "Sorry, something went wrong while processing the request. Please try again later."

---
- test: NavigateCompareIntent_mut_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "MUTATIONS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one and TP53 mutations are found in 63.6 and 93.9 percent of cancer types respectively. Across all of TCGA, Braca one is mutated in 7.9 percent of all cases while TP53 is mutated in 70 percent"

---
- test: NavigateCompareIntent_mut_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "MUTATIONS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Breast invasive carcinoma patients have more mutations in TP53 at 30 percent while 1.9 percent of cases have Braca one mutations."

---
- test: NavigateCompareIntent_mut_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "MUTATIONS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one is mutated more frequently in Ovarian serous cystadenocarcinoma at 3.2 percent while 1.9 percent of Breast invasive carcinoma cases have mutations."

---
- test: NavigateCompareIntent_mut_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "MUTATIONS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Breast invasive carcinoma patients, Pik 3 CA is the top mutated gene at 33.1 while TP53 is most mutated in Ovarian serous cystadenocarcinoma at 70 percent."

---
- test: NavigateCompareIntent_ind_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one and TP53 indels are found in 21.2 and 78.8 percent of cancer types respectively. Across all of TCGA, Braca one is mutated in 1.2 percent of all cases while TP53 is mutated in 12.1 percent"

---
- test: NavigateCompareIntent_ind_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Breast invasive carcinoma patients have more indels in TP53 at 5.7 percent while 0.3 percent of cases have Braca one indels."

---
- test: NavigateCompareIntent_ind_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one is mutated more frequently in Ovarian serous cystadenocarcinoma at 1.1 percent while 0.3 percent of Breast invasive carcinoma cases have indels."

---
- test: NavigateCompareIntent_ind_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "INDELS"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Breast invasive carcinoma patients, GATA3 is the top mutated gene at 8.3 while TP53 is most mutated in Ovarian serous cystadenocarcinoma at 11.7 percent."

---
- test: NavigateCompareIntent_snv_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "SNV"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one and TP53 SNVs are found in 63.6 and 93.9 percent of cancer types respectively. Across all of TCGA, Braca one is mutated in 7.4 percent of all cases while TP53 is mutated in 61.4 percent"

---
- test: NavigateCompareIntent_snv_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "SNV"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Breast invasive carcinoma patients have more SNVs in TP53 at 24.4 percent while 1.6 percent of cases have Braca one SNVs."

---
- test: NavigateCompareIntent_snv_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "SNV"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one is mutated more frequently in Ovarian serous cystadenocarcinoma at 2.1 percent while 1.6 percent of Breast invasive carcinoma cases have SNVs."

---
- test: NavigateCompareIntent_snv_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "SNV"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Among Breast invasive carcinoma patients, Pik 3 CA is the top mutated gene at 31.8 while TP53 is most mutated in Ovarian serous cystadenocarcinoma at 58.7 percent."

---
- test: NavigateCompareIntent_exp_G_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "TP53"
        data_type: "GENE_EXPRESSION"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "braca one"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "This compare operation is not supported."

---
- test: NavigateCompareIntent_exp_GS_vs_G
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GENE_EXPRESSION"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "TP53"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "In Breast invasive carcinoma, Braca one is expressed lower than TP53 with mean FPKM of 9.1 and 11.3, respectively."

---
- test: NavigateCompareIntent_exp_GS_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        gene_name: "BRCA1"
        study_abbreviation: "BRCA"
        data_type: "GENE_EXPRESSION"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "Braca one is expressed higher in Breast invasive carcinoma compared to Ovarian serous cystadenocarcinoma with mean FPKMs of 9.1 and 8.3, respectively."

---
- test: NavigateCompareIntent_exp_S_vs_S
- NavigateCompareIntent:
  - request.session.attributes:
      MELVIN.STATE:
        study_abbreviation: "BRCA"
        data_type: "GENE_EXPRESSION"
  - request.request.intent.slots:
      query:
        name: "query"
        value: "ovarian cancer"
        confirmationStatus: "NONE"
  - response.outputSpeech.ssml: "This compare operation is not supported."
